11/12 Late treatment study
et al., Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-139065 (Peer Reviewed)
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)
53% reduction in PCR+ with high-dose cholecalciferol supplementation. RCT with 16 treatment patients and 24 control patients.Relative risk of PCR+ at 2 weeks with treatment, RR 0.47, p=0.1825(OH)D levels at day 14 were 52 ng/ml vs. 15 ng/ml in the intervention and control group.
Rastogi et al., 11/12/2020, Randomized Controlled Trial, India, South Asia, peer-reviewed, 8 authors, dosage 60,000IU days 1-7.
risk of no virological cure, 52.6% lower, RR 0.47, p = 0.02, treatment 6 of 16 (37.5%), control 19 of 24 (79.2%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.